Therapeutic efficacy of new nitroimidazoles for experimental trichomoniasis, amebiasis, and trypanosomiasis.
D000562:Amebiasis / Q000188:drug therapy*; D000818:Animals; D000981:Antiprotozoal Agents / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D004748:Entamoeba histolytica / Q000187:drug effects; D005260:Female; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D051379:Mice; D008826:Microbial Sensitivity Tests; D009603:Nitroso Compounds / Q000494:pharmacology; D010303:Paromomycin / Q000627:therapeutic use; D051381:Rats; D013266:Stilbamidines / Q000627:therapeutic use; D014244:Trichomonas / Q000145:classification / Q000187:drug effects; D014245:Trichomonas Infections / Q000188:drug therapy*; D014345:Trypanosoma / Q000145:classification / Q000187:drug effects; D014352:Trypanosomiasis / Q000188:drug therapy*
D000981:Antiprotozoal Agents; D007093:Imidazoles; D009603:Nitroso Compounds; D013266:Stilbamidines; D008795:Metronidazole; D010303:Paromomycin